Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Belite BioSTU:D01 +1.55%20 Forward Dividend Yield % is 0.00% as of Jul. 17, 2026. GuruFocus rates STU:D01 with a GF Score™ of 20/100. The stock has 3 warning signs investors should review. Among 149 Biotechnology companies, Belite Bio ranks worse than 671140.27% on this metric.
As of today (2026-07-17), the Forward Annual Dividend Yield of Belite Bio is 0.00%.
As of today (2026-07-17), the Trailing Annual Dividend Yield of Belite Bio is 0.00%.
STU:D01's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.31 * Ranked among companies with meaningful Forward Dividend Yield % only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Belite Bio (STU:D01) Forward Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
STU:D01 vs DFTX, LGND, XENE: Forward Dividend Yield % Comparison
For the Biotechnology subindustry, Belite Bio's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Belite Bio Forward Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Belite Bio's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Belite Bio's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
Belite Bio (STU:D01) has a Forward Dividend Yield % of 0.00% as of Jul. 17, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Belite Bio and its competitors. According to the industry distribution chart, Belite Bio ranks #999999 out of 149 companies in the Biotechnology industry.
Is Belite Bio's Forward Dividend Yield % too high?
Belite Bio's current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Belite Bio ranks #999999 out of 149 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Belite Bio has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Belite Bio's Forward Dividend Yield % compare to DFTX and LGND?
According to the Biotechnology industry distribution chart, Belite Bio ranks #999999 out of 149 companies for Forward Dividend Yield %. This places Belite Bio in the lower half of its industry. The industry median Forward Dividend Yield % is 1.31. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.31, based on 149 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Belite Bio and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Belite Bio's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Belite Bio stock overvalued right now?
Belite Bio (STU:D01) has a current Forward Dividend Yield % of 0.00%. The current Forward Dividend Yield % is 0.00%. Belite Bio's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Belite Bio (STU:D01), the current Forward Dividend Yield % is 0.00% as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.
20GF Score
Get the complete analysis for STU:D01
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:D01 has been successfully added to your 
